Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6159718 | The Journal of Urology | 2008 | 11 Pages |
Abstract
Androgen deprivation therapy increases obesity, decreases insulin sensitivity and adversely alters lipid profiles. It may be associated with a greater incidence of diabetes and cardiovascular disease. The benefits of androgen deprivation therapy should be weighed against these and other potential harms. Little is known about the optimal strategy to mitigate the adverse metabolic effects of androgen deprivation therapy. Thus, we recommend an emphasis on existing strategies for screening and treatment that have been documented to reduce the risk of diabetes and cardiovascular disease in the general population.
Keywords
ADTCHDAHRGnRHIGTPSAOGTTFPGIFGSCDEORTCHDLRTOGNCEP ATP IIIOral glucose tolerance testProstate specific antigenMyocardial infarctiongonadotropin-releasing hormone agonistsimpaired glucose toleranceImpaired fasting glucoseAmerican Diabetes AssociationNational Cholesterol Education Program Adult Treatment Panel IIIcoronary heart diseaseCardiovascular diseasesADT, Androgen deprivation therapyDiabetes mellitusEuropean Organization for the Research and Treatment of CancerCancer of the Prostate Strategic Urologic Research EndeavorSEERbody mass indexBMIcardiovascularFasting plasma glucosehigh density lipoproteinlow density lipoproteinLDLObesitySudden cardiac deathProstatic neoplasmsadjusted hazard ratioSurveillance, Epidemiology and End ResultsGonadotropin-releasing hormoneADARadiation therapyCaPSURERadiation Therapy Oncology Group
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Philip J. Saylor, Matthew R. Smith,